Litigation Details for Aptalis Pharma US, Inc. v. Delcor Asset Corporation (D. Del. 2015)

Aptalis Pharma US, Inc. v. Delcor Asset Corporation (D. Del. 2015)

Docket		Date Filed	2015-12-27
Court	District Court, D. Delaware	Date Terminated	2016-04-19
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	8,217,083; 8,436,051
Link to Docket	External link to docket

Details for Aptalis Pharma US, Inc. v. Delcor Asset Corporation (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-12-27				External link to document
2015-12-26	1		expiration of U.S. Patent No. 7,541,384, U.S. Patent No. 8,217,083, and U.S. Patent No. 8,436,051. …Court. Count III: Infringement of U.S. Patent No. 8,217,083 38. Aptalis repeats and incorporates…Declaratory Judgment of Infringement of U.S. Patent No. 8,217,083 49. Aptalis repeats and incorporates…PageID #: 4 10. U.S. Patent No. 7,541,384 (“the ‘384 patent”) (attached as Exhibit A), titled…the U.S. Patent and Trademark Office (“USPTO”) on June 2, 2009. 11. U.S. Patent No. 8,217,083	External link to document
2015-12-26	4		Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,541,384; 8,217,083; 8,436,051. (…2015 19 April 2016 1:15-cv-01210 830 Patent None District Court, D. Delaware	External link to document
2015-12-26	7		Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,541,384; 8,217,083; 8,436,051. (…2015 19 April 2016 1:15-cv-01210 830 Patent None District Court, D. Delaware	External link to document

Litigation summary and analysis for: Aptalis Pharma US, Inc. v. Delcor Asset Corporation (D. Del. 2015)

Last updated: April 26, 2026

What is the litigation posture and what does it mean for Aptalis Pharma US, Inc. v. Delcor Asset Corporation (1:15-cv-01210)?

Aptalis Pharma US, Inc. (Aptalis) v. Delcor Asset Corporation (Delcor), 1:15-cv-01210, is a federal case in the U.S. District Court docketed in 2015. The matter centers on a patent and/or Hatch-Waxman-related commercial dispute between a brand/pharma rights holder and an asset/financing entity, with filings consistent with a litigation structure where ownership, licensing, enforcement rights, and/or drug-specific patent rights are contested through motions and claims typical of the pharmaceutical patent enforcement ecosystem.

However, the record is not sufficiently specified in the information provided here to produce a complete litigation summary (claims asserted, asserted patents, requested relief, procedural history, claim construction posture, motion outcomes, settlement/disposition, and any precedential holdings).

No complete and accurate litigation summary can be produced from the provided inputs.

---

What court and case timeline information is available from the provided citation?

The only concrete data present is the case caption and docket number:

Field	Value
Case	Aptalis Pharma US, Inc. v. Delcor Asset Corporation
Docket	1:15-cv-01210
Year	2015

---

What claims and patent issues does the case involve?

The provided prompt does not include:

• the complaint (asserted causes of action)
• the answer or counterclaims
• any amended pleadings
• the list of patents or drug(s) at issue
• a claim chart, infringement theory, validity challenge, or inequitable conduct allegations
• any Markman materials or claim construction results
• any Hatch-Waxman details (listed patents, paragraph IV, 30-month stay mechanics)
• the judgment or final order text

Without these, any attempt to describe “what the case is about” at the level of patent numbers, legal theories, and outcomes would be incomplete.

---

What litigation outcomes are available?

The prompt does not include dispositive outcomes or docket disposition (dismissal, summary judgment, settlement, consent judgment, appeal, or remand). Without an order or docket status, it is not possible to state:

• whether the case was dismissed on jurisdiction, standing, failure to state a claim, or preclusion
• whether any patent validity/infringement issues were resolved
• whether a preliminary injunction or other interim relief occurred
• whether the case ended in settlement terms affecting enforcement or licensing

---

Business and R&D implications

In pharmaceutical patent disputes, the business impact typically flows from:

• which patents are asserted and their remaining term
• whether enforceability is upheld
• whether licensing, assignment, or ownership is validated
• whether damages and injunctive relief are available
• whether the brand claims survive procedural challenges

But those depend on the specific procedural and substantive record that is not present.

---

Key Takeaways

• The provided information identifies the case and docket number only: Aptalis Pharma US, Inc. v. Delcor Asset Corporation, 1:15-cv-01210 (2015).
• The prompt does not include the complaint, asserted patents, legal claims, procedural history, or disposition needed to produce a complete litigation summary and analysis.
• No accurate, business-usable infringement/validity/enforceability conclusions can be supported from the current inputs.

---

FAQs

1. What is the docket number for Aptalis Pharma US v. Delcor Asset?
   1:15-cv-01210.

2. What is the jurisdiction and court for 1:15-cv-01210 based on the prompt?
   Not provided in the prompt.

3. Which patents or drug products are at issue?
   Not provided in the prompt.

4. What was the final outcome of the case?
   Not provided in the prompt.

5. Is the case likely a Hatch-Waxman enforcement matter?
   The prompt does not provide enough record detail to state that as fact.

---

References

[1] Aptalis Pharma US, Inc. v. Delcor Asset Corporation, No. 1:15-cv-01210 (Docket).